Barcelona, Spain, December 21st, 2020 – Peptomyc S.L., a biotech company specialized in the development of protein and peptide therapeutics for cancer treatment, announces that it has officially transitioned from pre-clinical to Clinical Stage, having filed its first Clinical Trial Application in Europe. The company has recently completed the pre-clinical safety studies for its first-in-class MYC inhibitor, OMO103. MYC is an oncoprotein deregulated in most –if not all- types of cancer. Accordingly, OMO103 has demonstrated potent anti-tumor activity in multiple preclinical models of cancer, and is now ready to be tested in Phase I/II clinical studies. The treatment of the first patient with is expected to start in Q1, 2021. 

Manuela Niewel, MD, PhD, as Chief Medical Officer of the company, will assume the responsibility for leading Peptomyc’s clinical development, regulatory and medical affairs activities. “I am really excited about this important step and look forward to seeing OMO103 successfully acting in patients”, Dr. Niewel says. ” With OMO-103, we will address three major unmet medical needs in the oncology field: Non-Small-Cell Lung Cancer, Triple Negative Breast Cancer, and Colorectal Cancer. 

The Phase I dose-escalation will start in three Spanish sites and later, in Phase II, we will expand the study to additional European sites”. 

Marie-Eve Beaulieu, PhD, co-founder and Chief Scientific Officer of Peptomyc adds: “The demonstration of our product’s quality, safety and stability, clearly represents a key milestone in our efforts to develop potentially life-saving cancer drugs. We are definitely thrilled to continue advancing Myc inhibition towards marketing approval”. 


About Peptomyc 

Peptomyc (www.peptomyc.com) is a spin-off from VHIO – the Vall d’Hebron Institute of Oncology – and ICREA – the Catalan Institute of Research and Advanced Studies -, founded in December 2014 in Barcelona, Spain. The company is focused on the development of innovative cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment and based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years. 

Disclosures Regarding Forward-Looking Statements 

Peptomyc is including the following cautionary statement in this document to make applicable and take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 (or equivalent law) for any forward-looking statements made by, or on behalf of, the Company. Forward-looking statements include statements concerning plans, objectives, goals, projections, strategies, future events or performance, and underlying assumptions and other statements which are other than statements of historical facts. Certain statements contained herein, including, without limitation, those that are identified by the use of the words “anticipates,” “estimates,” “expects,” “forecasts,” “intends,” “plans,” “predicts, “projects,” “believes,” “seeks,” “will,” “may” and similar expressions, are “forward-looking statements”. Forward-looking statements involve risks and uncertainties, which could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. The Company’s expectations, beliefs and projections are expressed in good faith and are believed by the Company to have a reasonable basis, but there can be no assurance that management’s expectations, beliefs, or projections will result or be achieved or accomplished.